← Back to Search

Vitamin B3 Analog

Nicotinamide for Skin Cancer Prevention (SPRINTR-Pilot Trial)

Phase 2
Waitlist Available
Led By Joseph Kim, MD PhD
Research Sponsored by Women's College Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

SPRINTR-Pilot Trial Summary

This trial will test if a drug called nicotinamide can help prevent skin cancer in people who have had organ transplants. If it is successful, it will become a larger trial.

Eligible Conditions
  • Non-melanoma Skin Cancer
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma

SPRINTR-Pilot Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Drug interactions
Feasibility (pertaining to adherence to follow-up assessments)
Feasibility (pertaining to adherence to intervention)
+5 more
Secondary outcome measures
Baseline prevalence of cognitive impairment (substudy)
Feasibility of recruiting for neurocognitive substudy
Pooled standard deviation of Animal Naming Task scores (substudy)
+6 more

Side effects data

From 2022 Phase 2 trial • 46 Patients • NCT03061474
25%
Diarrhoea
17%
Fall
17%
Urinary tract infection
8%
Vomiting
8%
Anxiety
8%
Back pain
8%
Laboratory test abnormal
8%
Constipation
4%
Head Injury
4%
Transaminases increased
4%
Urticaria
4%
Dyspepsia
4%
Upper respiratory tract infection
4%
Arthralgia
4%
Rash
4%
Fungal infection
4%
Penile ulceration
4%
Syncoper
4%
Foot fracture
4%
Osteoporosis
4%
Tooth abscess
4%
Agitation
4%
Weight decreased
4%
Blood testosterone decreased
4%
Hiatus hernia
4%
Pleocytosis
4%
Actinic keratosis
4%
Foot deformity
4%
Headache
4%
Neuropathy peripheral
4%
Thrombocytopenia
4%
Hyperlipidaemia
4%
Limb injury
4%
Viral upper respiratory tract infection
4%
Miliaria
4%
Diabetes mellitus
4%
Myalgia
4%
Colitis ulcerative
4%
Infection
4%
Cognitive disorder
4%
Renal cyst
4%
Parkinson's disease
4%
Pneumonia
4%
Laceration
4%
Dehydration
4%
Tremor
4%
Cancer surgery
4%
Glomerular Ffiltration rate decreased
4%
Dizziness
4%
Hypokalaemia
4%
Psoriasis
4%
Dysgeusia
4%
Post lumbar puncture syndrome
4%
Colorectal cancer
4%
Vitamin D deficiency
4%
Eructation
4%
Basal cell carcinoma
4%
Coccydynia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Nicotinamide

SPRINTR-Pilot Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: NicotinamideExperimental Treatment1 Intervention
Group II: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotinamide
2021
Completed Phase 3
~2810

Find a Location

Who is running the clinical trial?

NOW FoodsOTHER
5 Previous Clinical Trials
571 Total Patients Enrolled
1 Trials studying Non-melanoma Skin Cancer
396 Patients Enrolled for Non-melanoma Skin Cancer
The Kidney Foundation of CanadaOTHER
14 Previous Clinical Trials
2,845 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,348 Previous Clinical Trials
26,455,465 Total Patients Enrolled
2 Trials studying Non-melanoma Skin Cancer
2,954,144 Patients Enrolled for Non-melanoma Skin Cancer

Media Library

Nicotinamide (Vitamin B3 Analog) Clinical Trial Eligibility Overview. Trial Name: NCT03769285 — Phase 2
Non-melanoma Skin Cancer Research Study Groups: Nicotinamide, Placebo
Non-melanoma Skin Cancer Clinical Trial 2023: Nicotinamide Highlights & Side Effects. Trial Name: NCT03769285 — Phase 2
Nicotinamide (Vitamin B3 Analog) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03769285 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What purpose is Nicotinamide most regularly utilized for?

"Nicotinamide is often employed to address nutrient deficiencies, nutritional supplements, and dietary therapies."

Answered by AI

How many participants are registered for this research project?

"This investigation is not accepting participants currently; it was initially posted on December 3rd 2018 and most recently edited on February 9th 2022. However, if you are seeking other trials, there are presently 2710 studies recruiting patients suffering from carcinoma squamous cell as well as 12 clinical investigations needing participants with Nicotinamide related illnesses."

Answered by AI

Has Nicotinamide been given the greenlight by the Food & Drug Administration?

"Since this is a Phase 2 trial, there are some safety data but no efficacy information available. Therefore, the team at Power gave Nicotinamide an intermediate rating of two on their scale of 1-3."

Answered by AI

Is enrollment currently available to those interested in participating?

"Per the information presented on clinicaltrials.gov, this trial is not presently accepting participants as it has not been updated since February 9th 2022. However, there are 2,722 other medical studies actively enrolling patients at present time."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
2018. "Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03769285.
~19 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top